We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
MedXY AI/MedXY News/Tag: Apixaban
MedXY News
EnglishTag

Apixaban

Ask MedXY AI
type 2 diabetesclinical trialheart failureimmunotherapyobesitycardiovascular riskatrial fibrillationbiomarkerscritical careclinical trialsHypertensionartificial intelligenceCardiologyoncologypublic healthtype 1 diabetesdiabetesMortalityAlzheimer's diseasecardiovascular diseasebreast cancerepidemiology

Latest news

Tag

Hypertension-Related High-Risk Features May Identify Which Patients With Cryptogenic Stroke Benefit From Apixaban Instead of Aspirin
CardiologyApixabanAtrial Cardiopathy

Hypertension-Related High-Risk Features May Identify Which Patients With Cryptogenic Stroke Benefit From Apixaban Instead of Aspirin

By MedXY|Jun 10, 2026

An exploratory ARCADIA analysis suggests that patients with cryptogenic stroke and atrial cardiopathy without severe hypertension-related features may derive greater benefit from apixaban than aspirin, whereas those with high-risk hypertens

Apixaban in Subclinical Atrial Fibrillation: More Major Bleeds Driven by GI Events but Not by Intracranial or Fatal Hemorrhage
CardiologyApixaban
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
major bleeding

Apixaban in Subclinical Atrial Fibrillation: More Major Bleeds Driven by GI Events but Not by Intracranial or Fatal Hemorrhage

By MedXY|Nov 14, 2025

In ARTESiA patients with device-detected subclinical AF, apixaban reduced thromboembolism but increased major bleeding—primarily noncritical gastrointestinal events—while intracranial and fatal bleeding rates were similar to aspirin.

Apixaban Versus Aspirin for Recurrent Stroke Prevention in Patients with Left Ventricular Dysfunction: Insights from a Secondary Analysis of the ARCADIA Trial
CardiologyApixabanARCADIA Trial

Apixaban Versus Aspirin for Recurrent Stroke Prevention in Patients with Left Ventricular Dysfunction: Insights from a Secondary Analysis of the ARCADIA Trial

By MedXY|Oct 29, 2025

A secondary analysis of the ARCADIA trial reveals that apixaban significantly reduces recurrent ischemic stroke risk compared to aspirin in patients with left ventricular systolic dysfunction post-cryptogenic stroke.

Optimizing Extended Apixaban Therapy for Venous Thromboembolism: Insights from Recent Randomized Trials
CardiologyanticoagulationApixaban

Optimizing Extended Apixaban Therapy for Venous Thromboembolism: Insights from Recent Randomized Trials

By MedXY|Oct 9, 2025

Extended low-dose apixaban significantly reduces recurrent venous thromboembolism (VTE) in patients with provoked VTE and enduring risk factors, with minimal major bleeding. Reduced-dose apixaban for cancer-associated VTE is equally effecti

Extended Apixaban Therapy Reduces Recurrent VTE Risk in Patients with Provoked Events and Enduring Risk Factors
CardiologyApixabanvenous thromboembolism

Extended Apixaban Therapy Reduces Recurrent VTE Risk in Patients with Provoked Events and Enduring Risk Factors

By MedXY|Oct 9, 2025

A randomized trial demonstrates that low-dose apixaban for 12 months significantly lowers symptomatic recurrent VTE risk after provoked events with enduring risk factors, with minimal major bleeding.

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities